Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Georg Behrens

Showing results (31-40 of 39) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 39 results.
The Journal of Antimicrobial Chemotherapy|June 13, 2021
Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIVAna González-Cordón, Lambert Assoumou, Graeme Moyle, et al.
The Journal of Antimicrobial Chemotherapy|August 4, 2023
Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravirAna González-Cordón, Lambert Assoumou, Graeme Moyle, et al.
HIV Medicine|August 8, 2022
Use of contraindicated antiretroviral drugs in people with HIV/HCV coinfections receiving HCV treatment with direct-acting antivirals-Results from the EuroSIDA studyMyroslava Nikolaichuk, Amanda Mocroft, Gilles Wandeler, et al.
AIDS (London, England)|July 24, 2019
Uptake and effectiveness of two-drug compared with three-drug antiretroviral regimens among HIV-positive individuals in EuropeBastian Neesgaard, Annegret Pelchen-Matthews, Lene Ryom, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 21, 2018
Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM StudyMaud Lemoine, Lambert Assoumou, Stephane De Wit, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 18, 2022
Screening HIV Patients at Risk for NAFLD Using MRI-PDFF and Transient Elastography: A European Multicenter Prospective StudyMaud Lemoine, Lambert Assoumou, Pierre-Marie Girard, et al.
Molecular & Cellular Proteomics : MCP|July 10, 2010
Naturally occurring human urinary peptides for use in diagnosis of chronic kidney diseaseDavid M Good, Petra Zürbig, Angel Argilés, et al.
Nature Communications|July 17, 2021
Consensus statement on the role of health systems in advancing the long-term well-being of people living with HIVJeffrey V Lazarus, Kelly Safreed-Harmon, Adeeba Kamarulzaman, et al.
Nature Medicine|July 12, 2016
International AIDS Society global scientific strategy: towards an HIV cure 2016Steven G Deeks, Sharon R Lewin, Anna Laura Ross, et al.
Pageof 4

Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
The Journal of Antimicrobial Chemotherapy|June 13, 2021
Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIVAna González-Cordón, Lambert Assoumou, Graeme Moyle, et al.
The Journal of Antimicrobial Chemotherapy|August 4, 2023
Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravirAna González-Cordón, Lambert Assoumou, Graeme Moyle, et al.
HIV Medicine|August 8, 2022
Use of contraindicated antiretroviral drugs in people with HIV/HCV coinfections receiving HCV treatment with direct-acting antivirals-Results from the EuroSIDA studyMyroslava Nikolaichuk, Amanda Mocroft, Gilles Wandeler, et al.
AIDS (London, England)|July 24, 2019
Uptake and effectiveness of two-drug compared with three-drug antiretroviral regimens among HIV-positive individuals in EuropeBastian Neesgaard, Annegret Pelchen-Matthews, Lene Ryom, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 21, 2018
Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM StudyMaud Lemoine, Lambert Assoumou, Stephane De Wit, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 18, 2022
Screening HIV Patients at Risk for NAFLD Using MRI-PDFF and Transient Elastography: A European Multicenter Prospective StudyMaud Lemoine, Lambert Assoumou, Pierre-Marie Girard, et al.
Molecular & Cellular Proteomics : MCP|July 10, 2010
Naturally occurring human urinary peptides for use in diagnosis of chronic kidney diseaseDavid M Good, Petra Zürbig, Angel Argilés, et al.
Nature Communications|July 17, 2021
Consensus statement on the role of health systems in advancing the long-term well-being of people living with HIVJeffrey V Lazarus, Kelly Safreed-Harmon, Adeeba Kamarulzaman, et al.
Nature Medicine|July 12, 2016
International AIDS Society global scientific strategy: towards an HIV cure 2016Steven G Deeks, Sharon R Lewin, Anna Laura Ross, et al.
Pageof 4